Specialty pharmacy helps Fred’s Super Dollar realize 12% growth in June
MEMPHIS, Tenn. — Fred's super Dollar reported a June sales increase of 12% to $212.9 million on Thursday. Excluding $7.4 million from last year's June sales for 56 subsequently closed locations, total sales increased 16% for the month. Comparable store sales for the month increased 1.6% compared with a decrease of 0.6% in the same period last year.
“The strong sales growth we experienced during June continued to reflect the recent expansion of our specialty pharmacy business, which accounted for approximately 11% of total sales," stated Jerry Shore, Fred's CEO. "On a comparable store basis, June sales were on the lower end of our expectations, reflecting softer retail pharmacy department script volume and increasing reimbursement rate pressures associated with preferred Medicare Part D networks, which affects both sales and margins. On the other hand, general merchandise sales showed improvement in June and, on a comparable store basis, were flat for the month.
Fred's recently hired A.T. Kearney, a management and drug sector consulting firm, to contend with the gross margin pressures that are impacting retail pharmacy operations across the industry, Shore said.
Fred's total sales for the first five months of fiscal 2015 increased 6% to $889.1 million. Excluding sales of $35.2 million from closed stores in 2014, total sales increased 10% for the first five months of 2015. On a comparable store basis, year-to-date sales increased 0.8% versus a decline of 1.3% for the year-earlier period.
During June, Fred's closed one Xpress pharmacy location.
Walgreens selects proven performer as CEO following strong Q3
DEERFIELD, Ill. — Walgreens Boots Alliance appears to be just getting started. The company posted third-quarter EPS of $1.02 for the period ended May 31, which was 15 cents better than analyst estimates of 87 cents. However, revenue for the quarter came in at $28.8 billion, up 48.4%, against consensus estimates of $29.6 billion. Domestic operations were up 5.3% to $20.4 billion.
Walgreens chairman James Skinner named Stefano Pessina acting CEO following the better-than-projected earnings result, noting that Pessina "is the very best person to achieve our vision to be a truly global healthcare champion."
The results justified financial analyst Jim Cramer's confidence in the company expressed Wednesday in a video from TheStreet. On Tuesday, Cramer outlined why Walgreens Boots Alliance was a good stock to hold.
“In just six months since the strategic combination that formed Walgreens Boots Alliance, we are beginning to make progress in our operations, as we were able to deliver another strong quarter," Pessina, executive vice chairman and now the official CEO, said. "Our Retail Pharmacy USA division produced a solid increase in comparable prescriptions filled in the quarter, along with improved retail front-end margins and very good cost control," he said. "The fourth quarter is typically the slowest quarter because of seasonality in the business while prescription reimbursement pressure continues to impact our pharmacies, making retail margin expansion and cost control as important as ever.”
“In Walgreens Boots Alliance’s initial six months as a newly combined company, Stefano has done an extraordinary job leading the new enterprise, focusing our strategy while enhancing our financial performance,” Skinner said. “The integration of Walgreens and Alliance Boots is proceeding exceptionally well, with Stefano’s vision for the company driving the organization forward.”
The Retail Pharmacy USA division, whose principal retail pharmacy brands are Walgreens and Duane Reade, had third quarter sales of $20.4 billion, an increase of 5.3% over the year-ago quarter. Total sales in comparable drug stores increased 6.3% compared with the same quarter a year ago. Comparable drug store retail sales increased 1.6% in the third quarter with an increase in basket size partially offset by lower customer traffic compared with last year’s third quarter.
Pharmacy sales, which accounted for 66.1% of division sales in the quarter, increased 7% compared with the year-ago quarter while pharmacy sales in comparable stores increased 9.1%. The division filled 226 million prescriptions (including immunizations) on a 30-day adjusted basis in the quarter, an increase of 3.8% over last year’s third quarter. Prescriptions filled in comparable stores increased 4.1% compared with the same quarter last year. For the quarter ending May 31, the division’s retail prescription market share in the U.S. on a 30-day adjusted basis increased 20 basis points over a year ago to 19.3%, as reported by IMS Health.
Walgreens in the U.S. opened or acquired 104 drug stores in the first nine months of fiscal 2015, including 34 relocations, and closed 37 locations. As of May 31, the division operated 8,240 drugstores across all 50 states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands.
Net earnings attributable to Walgreens Boots Alliance determined in accordance with GAAP for the fiscal 2015 third quarter increased 82.4% to $1.3 billion compared with the same quarter a year ago, while GAAP net earnings per diluted share increased 59.5% to $1.18 compared with the same quarter a year ago.
The company announced today a 6.7% increase to its quarterly dividend to 36 cents per share. The increased dividend was declared by the board of directors on July 8, is payable Sept. 11 o stockholders of record Aug. 19, and raises the annual rate from $1.35 per share to $1.44 per share. This marks the 40th consecutive year Walgreens Boots Alliance or its predecessor company, Walgreen Co., has raised the dividend. The company remains committed to a long-term dividend payout ratio target of 30%-35%.
The Retail Pharmacy International division, whose principal retail brands are Boots in the U.K., Thailand, Norway, the Republic of Ireland and The Netherlands, Benavides in Mexico and Ahumada in Chile, had third quarter sales of $3.3 billion. On a pro forma constant currency basis, comparable store sales in the third quarter increased 3.2% compared with the same period a year ago. GAAP operating income was $205 million, while adjusted operating income was $249 million.
The international division operated 4,565 pharmacy-led health and beauty retail stores in eight countries, a net increase of six stores since the end of the second quarter of fiscal 2015, for the period ended May 31.
Walgreens Boots Alliance also announced today that it has acquired Liz Earle Beauty, owner of the Liz Earle skincare brand. Liz Earle is an award-winning premium skincare range that uses naturally active ingredients and is recognized as one of the leading botanical brands in the U.K.
The Pharmaceutical Wholesale division, which mainly operates under the Alliance Healthcare brand, had third quarter sales of $5.7 billion. On a pro forma constant currency basis, sales increased 0.2% compared with the same period a year ago. GAAP operating income was $162 million, while adjusted operating income was $171 million.
PhRMA Foundation names president
WASHINGTON — The Pharmaceutical Research and Manufacturers of America Foundation on Tuesday named Eileen Cannon president.
“On behalf of our member companies and staff, I’d like to congratulate Eileen on her well-deserved promotion to president of the PhRMA Foundation,” stated John Castellani, president and CEO, PhRMA. “Over the past 15 years, Eileen’s leadership has been instrumental in helping to connect promising young researchers to resources that not only help launch their careers, but also help to advance critical new science that contributes to the drug discovery process for patients.”
This year, the foundation is celebrating its 50th anniversary and its tradition of fostering the development of highly-trained, top-quality scientists to help address the growing needs of stakeholders in the biopharmaceutical sector, including scientific and academic institutions, government and the biopharmaceutical industry. Having funded the research of more than 2,200 young scientists, the Foundation continues its contribution to the future of care for patients.
Cannon has played a central role in the foundation’s expansion during her tenure. Over the last several years, she has helped implement new initiatives in regulatory science, comparative effectiveness research, translational medicine and safe and effective prescribing.
Cannon’s leadership has also contributed to the development of new partnerships with national scientific organizations and government agencies, such as the National Institute of Health and the Foundation of the National Institute of Health. This collaboration has led to the creation of education initiatives that are critical to biopharmaceutical research and development, practicing physicians and patients.
Loading Post Please Wait...